{"organizations": [], "uuid": "57879cd1d37e22d1e02c650f0542dc868058b2c9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180110.html", "section_title": "Archive News &amp; Video for Wednesday, 10 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-staidson-beijing-biopharmaceutical/brief-staidson-beijing-biopharmaceuticals-sees-fy-2017-net-profit-could-rise-up-to-5-pct-idUSL4N1P52U3", "country": "US", "domain_rank": 408, "title": "BRIEF-Staidson Beijing BioPharmaceuticals sees FY 2017 net profit could rise up to 5 pct", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.204, "site_type": "news", "published": "2018-01-10T16:23:00.000+02:00", "replies_count": 0, "uuid": "57879cd1d37e22d1e02c650f0542dc868058b2c9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-staidson-beijing-biopharmaceutical/brief-staidson-beijing-biopharmaceuticals-sees-fy-2017-net-profit-could-rise-up-to-5-pct-idUSL4N1P52U3", "ord_in_thread": 0, "title": "BRIEF-Staidson Beijing BioPharmaceuticals sees FY 2017 net profit could rise up to 5 pct", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-staidson beijing biopharmaceuticals", "sentiment": "negative"}, {"name": "reuters) - staidson beijing biopharmaceuticals co ltd", "sentiment": "neutral"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 10 (Reuters) - Staidson Beijing BioPharmaceuticals Co Ltd\n* Says it sees FY 2017 net profit could rise by up to 5 percent, or to be 257.3 million yuan to 270.1 million yuan\n* Says the net profit of FY 2016 was 257.3 million yuan\n* Comments that increased income of polyethylene glycol electrolyte as main reason for the forecast\nSource text in Chinese: goo.gl/Rtxod1\nFurther company coverage: (Beijing Headline News)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["https://goo.gl/Rtxod1", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-10T16:23:00.000+02:00", "crawled": "2018-01-11T12:37:53.014+02:00", "highlightTitle": ""}